Generic Portal

TY - JOUR

T1 - Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

AU - Uthman, Laween

AU - Baartscheer, Antonius

AU - Bleijlevens, Boris

AU - Schumacher, Cees A.

AU - Fiolet, Jan W. T.

AU - Koeman, Anneke

AU - Jancev, Milena

AU - Hollmann, Markus W.

AU - Weber, Nina C.

AU - Coronel, Ruben

AU - Zuurbier, Coert J.

PY - 2018

Y1 - 2018

N2 - Aims/hypothesis Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na+ ([Na+](c)) and cytosolic Ca2+ ([Ca2+](c)) concentrations through inhibition of Na+/H+ exchanger (NHE). Here, we examine (1) whether the SGLT2i dapagliflozin (DAPA) and canagliflozin (CANA) also inhibit NHE and reduce [Na+](c); (2) a structural model for the interaction of SGLT2i to NHE; (3) to what extent SGLT2i affect the haemodynamic and metabolic performance of isolated hearts of healthy mice. Methods Cardiac NHE activity and [Na+](c) in mouse cardiomyocytes were measured in the presence of clinically relevant concentrations of EMPA (1 mu mol/l), DAPA (1 mu mol/l), CANA (3 mu mol/l) or vehicle. NHE docking simulation studies were applied to explore potential binding sites for SGTL2i. Constant-flow Langendorff-perfused mouse hearts were subjected to SGLT2i for 30 min, and cardiovascular function, O-2 consumption and energetics (phosphocreatine (PCr)/ATP) were determined. Results EMPA, DAPA and CANA inhibited NHE activity (measured through low pH recovery after NH4+ pulse: EMPA 6.69 +/- 0.09, DAPA 6.77 +/- 0.12 and CANA 6.80 +/- 0.18 vs vehicle 7.09 +/- 0.09; p <0.001 for all three comparisons) and reduced [Na+](c) (in mmol/l: EMPA 10.0 +/- 0.5, DAPA 10.7 +/- 0.7 and CANA 11.0 +/- 0.9 vs vehicle 12.7 +/- 0.7; p <0.001). Docking studies provided high binding affinity of all three SGLT2i with the extracellular Na+-binding site of NHE. EMPA and CANA, but not DAPA, induced coronary vasodilation of the intact heart. PCr/ATP remained unaffected. Conclusions/interpretation EMPA, DAPA and CANA directly inhibit cardiac NHE flux and reduce [Na+](c), possibly by binding with the Na+-binding site of NHE-1. Furthermore, EMPA and CANA affect the healthy heart by inducing vasodilation. The [Na+](c)-lowering class effect of SGLT2i is a potential approach to combat elevated [Na+](c) that is known to occur in heart failure and diabetes

AB - Aims/hypothesis Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na+ ([Na+](c)) and cytosolic Ca2+ ([Ca2+](c)) concentrations through inhibition of Na+/H+ exchanger (NHE). Here, we examine (1) whether the SGLT2i dapagliflozin (DAPA) and canagliflozin (CANA) also inhibit NHE and reduce [Na+](c); (2) a structural model for the interaction of SGLT2i to NHE; (3) to what extent SGLT2i affect the haemodynamic and metabolic performance of isolated hearts of healthy mice. Methods Cardiac NHE activity and [Na+](c) in mouse cardiomyocytes were measured in the presence of clinically relevant concentrations of EMPA (1 mu mol/l), DAPA (1 mu mol/l), CANA (3 mu mol/l) or vehicle. NHE docking simulation studies were applied to explore potential binding sites for SGTL2i. Constant-flow Langendorff-perfused mouse hearts were subjected to SGLT2i for 30 min, and cardiovascular function, O-2 consumption and energetics (phosphocreatine (PCr)/ATP) were determined. Results EMPA, DAPA and CANA inhibited NHE activity (measured through low pH recovery after NH4+ pulse: EMPA 6.69 +/- 0.09, DAPA 6.77 +/- 0.12 and CANA 6.80 +/- 0.18 vs vehicle 7.09 +/- 0.09; p <0.001 for all three comparisons) and reduced [Na+](c) (in mmol/l: EMPA 10.0 +/- 0.5, DAPA 10.7 +/- 0.7 and CANA 11.0 +/- 0.9 vs vehicle 12.7 +/- 0.7; p <0.001). Docking studies provided high binding affinity of all three SGLT2i with the extracellular Na+-binding site of NHE. EMPA and CANA, but not DAPA, induced coronary vasodilation of the intact heart. PCr/ATP remained unaffected. Conclusions/interpretation EMPA, DAPA and CANA directly inhibit cardiac NHE flux and reduce [Na+](c), possibly by binding with the Na+-binding site of NHE-1. Furthermore, EMPA and CANA affect the healthy heart by inducing vasodilation. The [Na+](c)-lowering class effect of SGLT2i is a potential approach to combat elevated [Na+](c) that is known to occur in heart failure and diabetes

U2 - 10.1007/s00125-017-4509-7

DO - 10.1007/s00125-017-4509-7

M3 - Article

C2 - 29197997

VL - 61

SP - 722

EP - 726

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 3

ER -